(Q34456578)

English

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome (English)

1 reference

Europe PubMed Central

2 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Saskia M Rombach

1

1 reference

Europe PubMed Central

2 August 2017

Johannes M F G Aerts

2

1 reference

Europe PubMed Central

2 August 2017

Ben J H M Poorthuis

3

1 reference

Europe PubMed Central

2 August 2017

Johanna E M Groener

4

1 reference

Europe PubMed Central

2 August 2017

Wilma Donker-Koopman

5

1 reference

Europe PubMed Central

2 August 2017

Erik Hendriks

6

1 reference

Europe PubMed Central

2 August 2017

Mina Mirzaian

7

1 reference

Europe PubMed Central

2 August 2017

Sijmen Kuiper

8

1 reference

Europe PubMed Central

2 August 2017

Frits A Wijburg

9

1 reference

Europe PubMed Central

2 August 2017

Carla E M Hollak

10

1 reference

Europe PubMed Central

2 August 2017

Gabor E Linthorst

11

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

19 October 2012

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

7

1 reference

Europe PubMed Central

2 August 2017

10

1 reference

Europe PubMed Central

2 August 2017

e47805

1 reference

Europe PubMed Central

2 August 2017

copyright license

Creative Commons Attribution 4.0 International

19 October 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Is globotriaosylceramide a useful biomarker in Fabry disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

6 July 2018

Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

27 October 2018

Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

27 October 2018

Elimination of antibodies to recombinant enzyme in Pompe's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

27 October 2018

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

27 October 2018

The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

27 October 2018

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3477102

27 October 2018

Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23094092

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefit of enzyme replacement therapy in Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23094092

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23094092

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23094092

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative

1 reference

https://pubmed.ncbi.nlm.nih.gov/23094092

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23094092

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23094092

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0047805

1 reference

Europe PubMed Central

2 August 2017

2012PLoSO...747805R

0 references

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34456578&oldid=1866349401"